November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Neoadjuvant immunotherapy and SBRT in HCC
Jun 22, 2024, 11:24

Neoadjuvant immunotherapy and SBRT in HCC

Matthias Guckenberger, Radiation Oncologist at University Hospital Zurich, shared a post on X:

Neoadjuvant immunotherapy and SBRT in HCC – 3 x 8Gy on days 1, 3, 5 – 2 cycles of tislelizumab, every 21 days

  • no delay of surgery, safe
  • objective response rate (mRECIST) 63.2% (12/19), 3/19 CR
  • pCR 2/19.

Neoadjuvant immunotherapy

Read further.
Source: Matthias Guckenberger/X